|
Monday, 08/02/2010
|
Optimization of Error Spending Approach in Clinical Trials
Michael Baron, The University of Texas at Dallas; Yi Zhong, The University of Texas at Dallas
9:05 AM
|
Evaluation of Common Statistical Methods in Randomized Delayed-Start Design of Progression Disease Clinical Trials
Bongin Yoo, Bristol-Myers Squibb; Thomas Kelleher, Bristol-Myers Squibb
9:35 AM
|
Should the Conditional Type I Error Be Controlled?
Tie-Hua Ng, FDA
9:50 AM
|
Two-Stage Designs with Additional Futility Tests for Phase II Clinical Trials with Heterogeneous Patient Populations
Myron N. Chang, University of Florida; Sin-Ho Jung, Duke University
10:05 AM
|
Pitfalls of Simplistic Normalization in Basic Science Experiments
Tatsuki Koyama, Vanderbilt University School of Medicine; Zhiguo Zhao, Vanderbilt University School of Medicine; Jeffrey Blume, Vanderbilt University School of Medicine
10:50 AM
|
The Occasionally High Type I Error Rate of the Mantel-Haenszel Statistic Used in Detecting Differential Item Functioning and an Empirical Bayes Solution
Sandip Sinharay, Educational Testing Service; Neil J. Dorans, Educational Testing Service
10:55 AM
|
Method of Balanced Adjustment in Testing Coprimary Endpoints
George Kordzakhia, FDA
2:05 PM
|
Properties of Empirical Bayes Estimators for Evaluating Questionnaire Data in Epidemiology Studies
Jaya M. Satagopan, Memorial Sloan-Kettering Cancer Center; Qin Zhou, Memorial Sloan-Kettering Cancer Center; Susan Oliveria, Memorial Sloan-Kettering Cancer Center; Stephen Dusza, Memorial Sloan-Kettering Cancer Center; Martin Weinstock, Brown University; Marianne Berwick, University of New Mexico; Allan Halpern, Memorial Sloan-Kettering Cancer Center
2:35 PM
|
How to Estimate Measurement Error Variance Associated with Ancestry Proportion Estimates
Jasmin Divers, Wake Forest University Health Sciences; David T. Redden, The University of Alabama at Birmingham; Raymond J. Carrol, Texas A&M University; David B. Allison, The University of Alabama at Birmingham
3:05 PM
|
|
Wednesday, 08/04/2010
|
Multiplicity Adjustment in Clinical Trials
Annpey Pong, Merck & Co., Inc.
|
Comparison of Statistical Models Adjusting for Baseline in the Analysis of Thorough QT/QTc Studies
Guowen (Gordon) Sun, sanofi-aventis; Hui Quan, sanofi-aventis
8:35 AM
|
QTc Model Misspecification May Cause Spurious Carryover Effects
Xiaodong Li, Merck & Co., Inc.; Andrea Maes, Novartis Pharmaceuticals Corporation; Deborah Panebianco, Merck & Co., Inc.
8:50 AM
|
A Theory for Testing Hypotheses Under Covariate-Adaptive Randomization
Jun Shao, University of Wisconsin-Madison; Xinxin Yu, University of Wisconsin-Madison; Bob Zhong, Johnson & Johnson
10:55 AM
|
|
Thursday, 08/05/2010
|
Selecting Covariance Structures in 3, 4, and 6 Period PK and PD Crossover Trials
Deborah Panebianco, Merck & Co., Inc.; Tom Bradstreet, Merck & Co., Inc.; Andrea Maes, Novartis Pharmaceuticals Corporation; Lata Maganti, Merck & Co., Inc.
9:20 AM
|
Design and Trial Operational Considerations for a Phase II Two-Stage Adaptive Trial
Weili He, Merck & Co., Inc.; Madhuja Mallick, Merck & Co., Inc.; Yevgen Tymofyeyev, Merck & Co., Inc.; James A. Bolognese, Cytel Inc.
10:55 AM
|
Spatial Scan Statistics with Overdispersion
Tonglin Zhang, Purdue University
11:15 AM
|
Analysis of Non-Negative, Continuously Distributed Data with Excessive Zeros
Huiling Li, sanofi-aventis; Lynn Wei, sanofi-aventis; Hui Quan, sanofi-aventis; Nanshi Sha, Columbia University
11:50 AM
|
|